CRISPR technology for genome editing

CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.

By combining the great science from our labs with these world-renowned academic and industry partners, we will be able to integrate this ground-breaking technology into our research and help accelerate the discovery of novel treatments for patients

Dr. Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development, AstraZeneca

LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

AZ_Science_strategies_THM 22 January 2015

AstraZeneca science strategies in emerging innovation clusters

The_PARP_THM 19 December 2014

The PARP inhibitor paradigm: a collaborative approach to cancer drug discovery

Targeting_escape_THM 10 December 2014

Targeting escape pathways to further personalise breast cancer treatment